You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Description of diabetes cohorts

From: Predictive performance of comorbidity measures in administrative databases for diabetes cohorts

  Cohort 1a(n=29,058) Cohort 2 (n=41,925)
  20-44 (n=3,901) 45-64 (n=10,659) 65-74 (n=7,757) 75+ (n=6,741) All 20-44 (n=3,901) 45-64 (n=10,659) 65-74 (n=7,757) 75+ (n=6,741) All
Demographics b
Age, mean (SD) 36.2 (6.3) 55.5 (5.6) 69.5 (2.8) 80.6 (4.6) 62.5 (15.0) 36.8 (5.8) 55.3 (5.6) 69.6 (2.9) 81.0 (4.8) 62.4 (15.0)
Female 52.1 44.1 46.0 53.5 47.9 52.3 43.9 44.9 54.5 47.8
Urban 58.3 53.0 48.7 46.3 51.0 55.6 53.4 51.1 47.8 51.8
  Missing <0.1 0.2 0.1 <0.1 0.1 0.1 0.2 0.1 <0.1 0.1
Income Quintile           
  Q1 (lowest) 32.7 26.1 25.8 27.1 27.1 32.5 25.7 24.4 25.0 26.1
  Q2 22.0 23.2 23.2 24.7 23.4 23.2 22.1 23.4 23.8 23.0
  Q3 15.4 16.2 17.1 19.1 17.0 14.4 16.4 17.5 19.1 17.0
  Q4 13.5 14.8 15.1 12.8 14.2 13.0 15.1 15.4 14.6 14.8
  Q5 (highest) 15.4 18.2 17.4 15.1 16.9 16.0 19.5 18.0 16.4 17.9
  Missing 0.9 1.5 1.5 1.1 1.3 1.0 1.3 1.4 1.2 1.2
Recent diagnosis 27.5 24.3 21.7 21.3 23.4 16.0 12.6 9.6 8.3 11.3
Outcomes (%) c
AMI 0.5 1.6 2.9 3.3 2.2 0.4 0.9 1.9 3.0 1.6
Stroke 0.3 1.0 2.7 3.7 2.0 0.2 0.7 1.8 2.9 1.4
LEA 0.3 0.8 1.2 1.3 1.0 0.3 0.9 0.9 0.6 0.8
ESRD 0.7 0.5 0.4 0.2 0.4 0.3 0.5 0.5 0.3 0.4
Mortality 0.9 4.0 10.0 22.0 9.4 1.2 3.0 8.4 21.5 8.4
Hosp., any 34.3 43.7 57.6 64.7 51.0 31.7 40.9 55.2 61.8 48.1
Hosp., diabetes 18.6 21.3 26.6 30.2 24.4 14.5 16.8 22.0 24.0 19.5
Comorbidity summary measures, mean (SD)
# diagnoses 6.0 (4.8) 6.2 (4.8) 6.7 (4.7) 7.4 (4.8) 6.6 (4.8) 6.2 (5.7) 6.8 (6.0) 7.9 (6.6) 8.9 (6.8) 7.5 (6.4)
Charlson score 0.4 (0.8) 0.6 (1.2) 0.9 (1.5) 1.2 (1.7) 0.8 (1.4) 0.4 (0.8) 0.6 (1.2) 1.0 (1.7) 1.3 (1.9) 0.8 (1.5)
# drugs 3.1 (3.2) 4.2 (3.5) 5.3 (3.6) 5.9 (3.8) 4.7 (3.7) 3.1 (3.3) 4.5 (3.7) 5.9 (3.8) 6.4 (4.0) 5.1 (3.9)
CDS 2.5 (3.1) 3.9 (3.5) 5.0 (3.6) 5.3 (3.6) 4.3 (3.6) 2.8 (3.4) 4.4 (3.8) 5.6 (3.7) 5.7 (3.7) 4.8 (3.8)
  1. aCohort 1 was defined using administrative data from fiscal years 1996/97 to 1997/98 and Cohort 2 was defined using data from 1996/97 to 2001/02; bNumbers reported are percentages unless otherwise indicated; cOutcomes were defined over a two-year observation period, SD Standard Deviation, Hosp Hospitalization, AMI Acute Myocardial Infarction; LEA Lower Extremity Amputation; ESRD End-Stage Renal Disease, CDS Chronic Disease Score.